newsfilter
← Latest News
Business Wire·

ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma

– 88% of patients with advanced stage classical Hodgkin Lymphoma in trial remained progression free at 24 months – – Investigational regimen that eliminates two commonly used chemotherapy agents, vinblastine and